Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346999 | 0.91 | FFAR4 (0.53) | SCN9AMRGPRX4FFAR4MAOBSLC6A4 | |
| SCHEMBL1346572 | 0.89 | NPC1 (0.45) | SCN9AMAOBSLC6A4PTPN1 | |
| SCHEMBL1346610 | 0.89 | SCN9A (0.44) | SCN9AMAOBPPARDPPARAHTR6 | |
| SCHEMBL1346554 | 0.89 | SCN9A (0.44) | SCN9AMAOBSLC6A4PTPN1 | |
| SCHEMBL1346346 | 0.89 | SCN9A (0.44) | SCN9AMAOBPPARDPPARAHTR6 | |
| SCHEMBL1347008 | 0.89 | SLC6A2 (0.48) | MAOBPPARASLC6A4HTR6 | |
| SCHEMBL1346701 | 0.88 | PTPN1 (0.48) | SCN9AMAOBSLC6A4PTPN1 | |
| SCHEMBL1346953 | 0.88 | FFAR4 (0.47) | FFAR4MAOBPPARASLC6A4FFAR1 | |
| SCHEMBL1346347 | 0.87 | PPARA (0.47) | SCN9AMRGPRX4FFAR4PPARASLC6A4 | |
| SCHEMBL1347060 | 0.85 | FFAR1 (0.53) | SCN9AFFAR4MAOBSLC6A4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | claimed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | claimed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| JP-2007511564-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | claimed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | claimed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-7968592-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | disclosed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | disclosed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | TRPC3, TRPV3, CACNA1D | SCN9A 690/4885MRGPRX4 2256/4885FFAR4 819/4885 |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | TRPC3, TRPV3, CACNA1D | SCN9A 690/4885MRGPRX4 2256/4885FFAR4 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.